Figure 2 | Scientific Reports

Figure 2

From: Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

Figure 2

ABCB1 polymorphism influences plasma imatinib levels and RNA Expression of ABC transporters influence intracellular Imatinib levels (b) Plasma imatinib levels on day29 post imatinib therapy in patients with ABCB1/MDR1 C1236T genotypes (wt (CC) n = 10; Het + Mut (CT + TT) n = 57). (b) Intracellular imatinib levels in patients with above or below median expression of ABCB1 (median expression-21.9), (c) ABCA3 (median expression-505 below median n = 23 vs above median n = 33) and (d) ABCC4 (median expression-28.4; below median n = 30 vs above median n = 26) RNA. The RNA expression of each gene was normalised to GAPDH and relative expression to CML001 using 2-ddCT method. Statistical significance was calculated using Mann–Whitney U test.

Back to article page